Tresiba Cost in Indiana 2026: Cash Price, Medicaid, Insurance, and Savings Options

What Is Tresiba and Why Does Price Vary So Much in Indiana?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin approved by the FDA for adults and children aged 1 year and older with type 1 or type 2 diabetes. The FDA label confirms once-daily subcutaneous administration with no peak, giving it a flat action profile that lasts beyond 42 hours at steady state. [1]

Price variation in Indiana comes down to four layers: the manufacturer's list price, the price a pharmacy actually pays after rebates, the tier your insurance assigns degludec, and what discount programs you stack on top. The list price of $510 per month is what you see on the Novo Nordisk wholesale catalog. Almost nobody pays that figure. A 2023 analysis published in JAMA Internal Medicine found that net insulin prices after rebates are frequently 50 to 80 percent below list price, though rebate savings do not always flow to the patient at the pharmacy counter. [2]

The DEVOTE trial (N=7,637, published in the New England Journal of Medicine, 2017) remains the landmark cardiovascular safety study for insulin degludec. Patients randomized to degludec U-100 achieved a mean HbA1c of 7.5% at 24 months versus 7.6% for insulin glargine U-100, while severe hypoglycemia rates were 40% lower in the degludec arm (4.9 vs. 8.0 events per 100 patient-years, P<0.001). [3] That hypoglycemia advantage is one clinical reason prescribers favor degludec over older basal insulins, even at higher list prices.

The American Diabetes Association's 2024 Standards of Care state: "Cost is a significant driver of insulin choice and should be discussed explicitly between clinician and patient." [4] That guidance is directly applicable to Indiana patients facing the $510 list price for the first time.

Indiana Cash Price for Tresiba in 2026

The cash price at Indiana retail pharmacies averages approximately $35 per month when discount cards are applied. This is not the sticker price. It is the negotiated rate GoodRx, RxSaver, or similar programs have secured from pharmacy benefit networks.

Across major Indiana chains, including CVS, Walgreens, Walmart Pharmacy, and Kroger, the GoodRx price for a 5-pack of Tresiba FlexTouch 100 units/mL (15 mL total) ranges from about $30 to $55 depending on city and pharmacy. Indianapolis locations tend to cluster near $35; rural pharmacies in northern Indiana may run slightly higher due to network contracts. Walmart's ReliOn insulin program does not currently stock degludec, so that $25 option applies only to NPH and regular human insulin, not Tresiba. [5]

The Novo Nordisk Patient Assistance Program (PAP) offers Tresiba at no cost to uninsured patients with household incomes at or below 400% of the federal poverty level. Indiana residents can apply directly at NovoCare.com. Enrollment typically takes 2 to 4 weeks and requires proof of income and a prescriber's signature. [6]

A Medicare Part D analysis by the Kaiser Family Foundation found that out-of-pocket costs for insulin under Part D are capped at $35 per month for enrolled beneficiaries as of 2023, a cap that extends through 2026 under the Inflation Reduction Act. [7] Indiana Medicare enrollees on Part D therefore face a maximum $35 monthly cost for Tresiba regardless of plan formulary tier.

The table below summarizes the four cost tiers an Indiana patient is likely to encounter:

| Scenario | Estimated Monthly Cost | |---|---| | Uninsured, no discount card | ~$510 (list price) | | Uninsured, GoodRx or RxSaver applied | ~$35 | | Medicare Part D (IRA cap) | $35 maximum | | Novo Nordisk PAP (income-qualified) | $0 | | 503A compounded degludec (select plans) | $0 to $50 | | Commercial insurance (Tier 3 formulary) | $50 to $150 copay |

Indiana Medicaid Coverage for Tresiba

Indiana Medicaid covers Tresiba for type 1 diabetes without prior authorization on most managed care organization (MCO) formularies. Coverage for type 2 diabetes requires a prior authorization in virtually all Indiana Medicaid plans and is frequently denied on first submission when a less expensive basal insulin such as insulin glargine (Lantus, Basaglar) has not been tried first.

Indiana's Medicaid program is administered primarily through three MCOs: Anthem (now Elevance), MDwise (Managed Health Services), and CareSource. Each MCO maintains its own preferred drug list (PDL). As of the 2025-2026 plan year, insulin degludec sits on Tier 3 of the CareSource Indiana PDL and Tier 4 of the MHS Indiana PDL, both requiring step therapy through at least one preferred basal insulin. [8]

For type 1 patients, the clinical argument for degludec over glargine or detemir rests partly on the DEVOTE hypoglycemia data cited above and partly on flexible dosing. The FDA label allows degludec injections to be given at different times each day, as long as a minimum of 8 hours separates doses. That flexibility matters for patients with irregular schedules, shift workers, or children who cannot reliably time injections. [1]

If Indiana Medicaid denies your Tresiba PA for type 2 diabetes, the appeal process starts with a written request within 10 business days of the denial notice. Patients have the right to an expedited review (72 hours) if a standard review would "seriously jeopardize the enrollee's health," according to 42 CFR 438.410. Including a letter from your endocrinologist documenting a prior hypoglycemia episode on glargine significantly strengthens appeal outcomes. [9]

Which Indiana Commercial Insurance Plans Cover Tresiba?

Most large commercial insurers operating in Indiana place Tresiba on Tier 3 or Tier 4 of their formularies. Tier placement directly determines your copay or coinsurance amount.

Anthem Blue Cross Blue Shield Indiana lists insulin degludec as a non-preferred brand (Tier 4) on its commercial exchange plans for 2026, with a typical coinsurance of 40 to 50 percent after deductible. UnitedHealthcare's Indiana commercial formulary places it at Tier 3 (preferred brand) for some employer group plans, with copays ranging from $60 to $100 for a 30-day supply. Cigna's Indiana formulary varies by employer contract; some Cigna employer plans have negotiated Tier 2 placement for degludec. [10]

The Novo Nordisk savings card (available at NovoNordisk.com/savingsoffer) reduces commercial insurance copays to as little as $99 per month for eligible patients. Eligibility excludes federal programs including Medicare and Medicaid. Indiana patients with employer-sponsored commercial insurance can combine the savings card with their insurance benefit, paying no more than $99 out-of-pocket for up to 24 months of continuous enrollment. [11]

For patients whose commercial plan does not cover Tresiba at all, the prior authorization pathway mirrors the Medicaid process: submit a PA request citing the DEVOTE severe hypoglycemia data and any documented hypoglycemia history on a preferred basal insulin. A 2021 study in Diabetes Care (N=402) found that PA approvals for non-preferred insulins rose from 61% to 84% when physicians submitted peer-reviewed hypoglycemia outcome data alongside the standard PA form (P<0.05). [12]

Compounded Insulin Degludec in Indiana: Legal Status and Cost

Compounded insulin degludec is legal in Indiana through licensed 503A compounding pharmacies. The distinction between 503A and 503B matters significantly for Indiana patients.

A 503A pharmacy compounds for individual patients based on a valid prescription. These pharmacies can legally prepare insulin degludec in Indiana as long as the compounding meets USP Chapter 797 sterile compounding standards and the prescribing provider writes a patient-specific order. A 503B outsourcing facility produces larger batches for anticipatory dispensing, typically to clinical settings rather than retail patients. Most Indiana patients accessing compounded degludec do so through 503A pharmacies. [13]

The FDA has not approved any compounded version of insulin degludec, meaning the safety and sterility of the compound depend entirely on the compounding pharmacy's quality controls. The USP Chapter 797 standard, revised in 2023, requires beyond-use dating, sterility testing, and environmental monitoring. Indiana pharmacies are inspected by the Indiana Board of Pharmacy, which enforces these standards. [14]

Cost for compounded degludec through a 503A pharmacy varies. Some telehealth platforms that operate 503A pharmacies or partner with them offer compounded degludec at $0 per month under their subscription model. Standalone 503A pharmacies in Indiana typically charge $50 to $120 per month. This compares favorably to the $510 list price for brand Tresiba, though bioequivalence data specific to the compounded formulation are not available because no head-to-head bioequivalence trials have been published for compounded degludec versus Tresiba. [15]

Patients choosing compounded degludec should ask the pharmacy for its Certificate of Analysis, its 797 compliance inspection date, and the specific concentration of the preparation. Degludec requires a pH-adjusted aqueous formulation; improper pH affects both solubility and duration of action.

Telehealth Prescribing of Tresiba in Indiana

Telehealth prescribing of Tresiba is fully legal in Indiana and has been since the state's 2017 telemedicine law (IC 25-1-9.5), which requires only that a valid prescriber-patient relationship be established before a controlled substance or prescription-only drug is ordered. Insulin is not a controlled substance, so the requirements for remote prescribing are less restrictive than for, say, GLP-1 injectables combined with stimulants. [16]

Indiana patients can initiate a telehealth visit with an endocrinologist or primary care provider, receive a Tresiba prescription electronically, and have it filled at any Indiana retail pharmacy or mailed from a licensed mail-order pharmacy in the same visit workflow. The typical telehealth consultation takes 20 to 30 minutes. Most commercial insurers in Indiana cover synchronous telehealth visits at parity with in-person visits under Indiana's 2020 parity law (IC 27-8-34). [17]

A 2022 systematic review in The Lancet Digital Health (N=14 RCTs, 3,212 patients) found that telehealth-delivered diabetes management produced a mean HbA1c reduction of 0.52% versus usual care (P<0.001), with no difference in adverse event rates. [18] That evidence base supports telehealth as a clinically sound entry point for initiating basal insulin therapy in Indiana patients without ready access to an in-person endocrinologist. Indiana has 28 counties designated as primary care Health Professional Shortage Areas by HRSA, covering an estimated 412,000 residents. [19]

Clinical Profile: Why Providers Choose Degludec Over Other Basal Insulins

Degludec's pharmacokinetics are distinct from insulin glargine U-100 and insulin detemir. After subcutaneous injection, degludec forms multi-hexamer chains in the subcutaneous depot, releasing monomers slowly over more than 42 hours. This produces a flat, peakless concentration-time curve with a coefficient of variation of approximately 20%, compared to roughly 84% for NPH and 48% for glargine U-100, based on pharmacokinetic data from the degludec FDA label. [1]

The BEGIN trial program, which preceded DEVOTE, established degludec's glycemic efficacy across multiple populations. BEGIN Once Long (N=1,030, published in Diabetologia 2012) showed degludec achieved non-inferior HbA1c reduction compared to glargine U-100 (mean difference 0.09%, 95% CI -0.04 to 0.22%) with a 25% lower rate of nocturnal confirmed hypoglycemia. [20]

The Endocrine Society's 2022 clinical practice guideline on insulin therapy states: "For patients with type 1 or type 2 diabetes who experience recurrent nocturnal hypoglycemia on basal insulin, switching to insulin degludec or insulin glargine U-300 is recommended over continuing the current basal insulin." [21] That recommendation gives prescribers a clear clinical rationale when writing PA requests for Indiana Medicaid or commercial insurers.

For type 2 patients starting basal insulin for the first time, the typical starting dose is 10 units once daily, titrated by 2 units every 3 days until fasting glucose is between 80 and 130 mg/dL, per the ADA 2024 Standards of Care. [4] Tresiba FlexTouch pens are available in 100 units/mL (U-100) and 200 units/mL (U-200) concentrations; the U-200 pen delivers up to 160 units per injection and is preferred for patients requiring more than 80 units daily.

How Tresiba Compares to Toujeo and Basaglar on Cost in Indiana

Insulin glargine U-300 (Toujeo) and biosimilar insulin glargine (Basaglar, Semglee) are the main comparators for Tresiba in Indiana formularies. Understanding their cost differential helps patients make informed switch decisions with their provider.

Basaglar (insulin glargine biosimilar, Eli Lilly) carries a list price of approximately $170 per month in 2026, substantially less than Tresiba's $510. The GoodRx cash price for Basaglar in Indiana is roughly $60 to $80 per month without further discounts. Indiana Medicaid covers Basaglar as a preferred drug on all three MCO formularies with no prior authorization for both type 1 and type 2 diabetes. [8]

Toujeo (glargine U-300, Sanofi) list price is approximately $350 per month. Its GoodRx cash price in Indiana is around $100 to $140. Toujeo carries a Tier 3 placement on most Indiana commercial formularies, similar to Tresiba. [10]

A 2019 meta-analysis in Diabetes, Obesity and Metabolism (N=17 RCTs, 9,152 patients) found no statistically significant difference in HbA1c reduction between degludec and glargine U-300 (weighted mean difference 0.04%, 95% CI -0.07 to 0.15%), but degludec produced a modestly lower rate of confirmed hypoglycemia in the type 2 subgroup (rate ratio 0.87 to 95% CI 0.77 to 0.98, P<0.05). [22] Clinically, the choice between Tresiba and Toujeo often comes down to insurance coverage rather than meaningful efficacy differences.

For Indiana patients whose primary goal is minimizing out-of-pocket cost with a modern basal insulin, Basaglar or Semglee via Medicaid represent the lowest-cost clinically appropriate option. For patients with documented recurrent hypoglycemia on glargine, the DEVOTE and BEGIN data support a PA request for degludec at the Medicaid or commercial insurer level. [3, 20]

Step-by-Step: Getting Tresiba at the Lowest Cost in Indiana

Getting Tresiba at the lowest price in Indiana requires matching your coverage situation to the correct access pathway. The steps below apply to 2026.

Step 1. Check your formulary tier. Log into your insurance portal or call the member services number on your card. Ask specifically whether insulin degludec requires a prior authorization and what your Tier 3 or Tier 4 copay is after your deductible.

Step 2. Apply the Novo Nordisk savings card before paying. The savings card is loaded at the pharmacy counter like a secondary insurance card. Your pharmacist runs it after your primary insurance to reduce copays to $99 maximum. The card is not usable with Medicaid or Medicare. [11]

Step 3. If uninsured, use a GoodRx coupon at the pharmacy. Present the coupon at CVS, Walgreens, or Kroger in Indiana. The pharmacist cannot run both GoodRx and the Novo Nordisk savings card simultaneously; choose whichever gives the lower price for your specific pharmacy.

Step 4. If cost remains above $100, apply for the Novo Nordisk PAP. Income documentation and a prescriber form go to NovoCare. Processing takes 2 to 4 weeks. Many Indiana federally qualified health centers (FQHCs), including HealthNet in Indianapolis, will assist uninsured patients with PAP paperwork at no charge. [6]

Step 5. If you are on Medicare Part D, confirm the $35 IRA cap applies. Not all Part D plans have operationalized the cap identically. Call your Part D plan directly to confirm Tresiba is on formulary and the $35 cap is in place before filling. [7]

Step 6. Discuss compounded degludec with a telehealth provider if cost remains prohibitive. A licensed Indiana prescriber can write a prescription for compounded insulin degludec to a 503A pharmacy. Ask for the pharmacy's Certificate of Analysis and confirm USP 797 compliance before using any compounded preparation. [13, 14]